Group 1 - Company and its subsidiaries received approval from the National Medical Products Administration for clinical trials of HRS-4508 tablets, SHR-A1811 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - HRS-4508 is a novel, efficient, selective tyrosine kinase inhibitor that inhibits tumor cell proliferation [1] - The total R&D investment for HRS-4508 project is approximately 36.42 million yuan [1] Group 2 - SHR-A1811 injection binds to HER2-expressing tumor cells and induces apoptosis through a unique mechanism [2] - SHR-A1811 was approved for use in treating adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations [2] - The total R&D investment for SHR-A1811 project is approximately 1.26 billion yuan [2] Group 3 - Bevacizumab is a humanized anti-VEGF monoclonal antibody that has been approved in multiple countries since 2004 [3] - The global sales of Bevacizumab are projected to be approximately 5.655 billion USD in 2024 [3] - The total R&D investment for Bevacizumab injection project is approximately 3.45 million yuan [3]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received orphan drug designation from the U.S. FDA for its product, injection of Rukang Trastuzumab in combination with Atezolizumab and chemotherapy for the treatment of gastric cancer or gastroesophageal junction adenocarcinoma, which will provide opportunities for policy support in product development, registration, and commercialization [1][4]. Group 1: Drug Information - Drug Name: Injection of Rukang Trastuzumab [1] - Indication: Used in combination with Atezolizumab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - Application Number: DRU-2025-10850 [1] - Approval Conclusion: Granted orphan drug status under Section 526 of the Federal Food, Drug, and Cosmetic Act [1]. Group 2: Market Context - In 2022, gastric cancer ranked 5th in global cancer incidence and mortality, with 968,400 new cases and 659,900 deaths worldwide [2]. - In China, there were 358,700 new cases and 260,400 deaths, ranking 5th in incidence and 3rd in mortality [2]. - Current first-line treatment standards have shown some clinical effectiveness but still face unmet clinical needs due to short survival times and poor prognosis [2]. Group 3: Drug Mechanism and Competition - Rukang Trastuzumab binds to HER2-expressing tumor cells, inducing apoptosis through a mechanism involving toxin release in lysosomes [3]. - The drug was approved for use in China in May 2025 for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received at least one systemic treatment [3]. - Competing products include Ado-trastuzumab emtansine (Kadcyla) and Fam-trastuzumab deruxtecan (Enhertu), with combined global sales projected at approximately $6.557 billion for 2024 [3]. Group 4: Impact of Orphan Drug Designation - The orphan drug designation will expedite clinical trial and registration processes [4]. - The company will benefit from policy support, including tax credits for clinical trial costs, waiver of new drug application fees, and seven years of market exclusivity post-approval [4].